Minutes

Date       Wednesday, 05/01/2022
Time       9:00 AM
To         Committee Members
At         Virtual via Microsoft Teams
Subject    AWERB 3Rs Committee

In Attendance: [Redacted]

Apologies: [Redacted]

Minutes - [Redacted]

1. Minutes
   The previous minutes were approved

2. Matters Arising
   [Redacted] discussed the possibility of meeting in person in March.

3. Retrospective Reviews
   The committee discussed the following:

   Proteostasis in lung disease
   - Section 2.5: More details needed about the non-use of the protocols 1 to 3.
   - Section 3.1: The committee advises to highlight the publication in the relevant section of the retrospective review (section 4.8)
   - Section 3.2: Further information needed on the use of primary human cell to replace animals - Details of the animal reduction number.

   Understanding how to exploit the oxygen sensing pathway for therapeutic benefit
   - Section 2.2: protocol 5, animal’s were returned with a severe severity. More information required regarding the reason for this higher severity.
   - Section 3.7: Several refinements are cited in this section and the committee would like to know if there are any publications or any being prepared highlighting these methods.
Mechanisms of metabolic disease

- Section 2.1: protocol, 9, 21 and 22 a number of animals returned as “non-recovery”. The protocols were classified as mild or moderate - Further details needed about this.

4. Amendments

5. Severe Severity

6. Severe Severity licence reviews

7. Standard condition 18 reports

8. 3Rs information/reports

\[ \text{reported that in AOC informed the committee of SC18 reports from a PPLh who has had 7 repeated incidents due to rapid tumour growth exceeding the 10% body weight limit. The NACWOs from the animal facility are aware of this and are monitoring the issue. In the 3Rs report, the use of restraints has been discussed.} \]

9. Highlights of AWERB Standing meeting*

10. Highlights of January AOC meeting*

11. Any Other Business

\[ \text{Hydrodynamic tail vein injection } \text{https://www.mirusbio.com/products/in-vivo/transit-qr-delivery-solution} \text{ - Discussed briefly as FIO} \]

\[ \text{Blood sampling via the saphenous vein poster to be reviewed by the committee. (Circulated with meeting documents) Discussed and final version will be circulated.} \]

12. For information only

Date of next meeting: 2\textsuperscript{nd} February 2022

*Items for information only unless un-starred by committee member